Yan Zou

Oct 28, 2024 | nature.com | Yang Liu |Xue Xia |Linlin Fan |Mengke Fang |Yan Zou |Meng Zheng | +3 more

AbstractStrategies that selectively bind proteins of interest and target them to the intracellular protein recycling machinery for targeted protein degradation have recently emerged as powerful tools for undruggable targets in biomedical research and the pharmaceutical industry. However, targeting any new protein of interest with current degradation tools requires a laborious case-by-case design for different diseases and cell types, especially for extracellular targets.

Oct 20, 2023 | mdpi.com | Yan Zou |Lichun Huang |Dong Zhao |Mengjie He

Article Menu/ajax/scifeed/subscribeAltmetricannouncementHelpformat_quoteCitethumb_up... EndorseNeed Help? Find support for a specific problem in the support section of our website. Please let us know what you think of our products and services. Visit our dedicated information section to learn more about MDPI.

Aug 26, 2023 | mdpi.com | Yan Zou |Lichun Huang |Mengjie He |Dong Zhao

This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticleby, , , , and * Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China*Author to whom correspondence should be addressed.

Jul 28, 2023 | nature.com | Yan Zou |Xin Wang

AbstractGlioblastoma (GBM) remains the most lethal malignant tumours. Gboxin, an oxidative phosphorylation inhibitor, specifically restrains GBM growth by inhibiting the activity of F0F1 ATPase complex V. However, its anti-GBM effect is seriously limited by poor blood circulation, the blood brain barrier (BBB) and non-specific GBM tissue/cell uptake, leading to insufficient Gboxin accumulation at GBM sites, which limits its further clinical application.